▌Top Stocks · DIVIDEND KINGS·Updated June 11, 2026
Inside Our Top Dividend Kings Stock Picks for 2026
These seven Dividend Kings combine long payout streaks with durable businesses, but McDonald’s, Procter & Gamble, and Colgate stand out most on overall quality.
Dividend Kings matter because they are one of the market’s clearest signals of durability. A company does not raise its payout for 50-plus consecutive years without surviving recessions, inflation shocks, rate swings, and multiple competitive cycles. That matters even more in today’s market, where investors are balancing slower growth, sticky costs, and the need for income streams that can keep compounding over time rather than simply offering a high headline yield.
This theme spans several business models, and that diversity is part of the appeal. Consumer staples names rely on brand power and pricing, healthcare leaders lean on recurring demand and broad product portfolios, industrial operators benefit from mission-critical equipment and automation, and restaurant franchisors can turn asset-light systems into dependable cash flow. Recent corporate actions reinforce the case: Procter & Gamble said in April 2026 that it had increased its dividend for 70 consecutive years, while Coca-Cola’s February 2026 board action marked its 63rd straight annual increase.
Still, not every Dividend King offers the same investment quality. For this list, the streak is only the starting point; the real question is whether the underlying business still shows pricing power, margin resilience, and enough earnings strength to support future dividend growth. The picks below are ranked in countdown order from No. 7 to No. 1, with the strongest overall quality profile appearing at the end.
We screened for U.S.-listed Dividend Kings with market capitalizations above $500 million, then ranked them by investment quality rather than yield alone. Our review emphasized profitability, earnings consistency, growth trends, valuation context, analyst sentiment, and composite quality grades built from primary-source financial data. Because this is a countdown, the list starts with the more qualified names that still carry notable trade-offs and ends with our top overall pick at No. 1.
What they do. The company provides industrial technology and software across final control, measurement and analytical tools, discrete automation, safety and productivity products, control systems, and test and measurement. Emerson’s portfolio includes valves, actuators, instrumentation, automation software, and plant-control systems sold across the Americas, Asia, the Middle East, Africa, and Europe, giving it a broad installed-base business tied to industrial operations.
Why it fits. Emerson represents the industrial side of the Dividend Kings theme, where resilience comes from mission-critical equipment rather than consumer brands. Products such as control valves, pressure safety systems, measurement devices, and DeltaV and Ovation software are embedded in customer workflows, which can support recurring demand and cash generation through different economic cycles.
Numbers that matter. Emerson generated $18.32 billion in revenue and $5.87 billion in EBITDA, with a 52.7% gross margin, 24.24% operating margin, and 13.35% net margin. Profitability is respectable, with ROE of 12.33% and ROA of 6.68%, while growth has been mixed but still solid: revenue rose 2.9% year over year and earnings grew 27.9%. Valuation is the main constraint, with a trailing P/E of 32.97 and forward P/E of 19.92, which helps explain why its composite quality grade is only a B despite decent operating performance.
Recent momentum. Emerson has beaten earnings estimates in 5 of the last 7 reported quarters, including a 0.7% beat in May 2026 and a 5.9% beat in February 2026. Analyst sentiment is cautious rather than bullish, with 3 Buy, 6 Hold, and 1 Sell ratings, though the average target of $163.72 still sits above current trading levels. That combination makes Emerson a credible Dividend King, but not the cleanest quality story in this group.
What they do. The company develops and sells healthcare products across four segments: established pharmaceuticals, diagnostics, nutrition, and medical devices. That breadth matters because Abbott is not dependent on a single therapy area; it participates in lab testing, point-of-care diagnostics, infant and adult nutrition, cardiovascular devices, diabetes care, and neuromodulation.
Why it fits. Abbott fits the Dividend Kings profile through recurring healthcare demand and a diversified product base that can smooth out volatility in any one category. Medical devices, diagnostics, and nutrition all support the kind of durable cash generation investors look for in long-lived dividend compounders, and the company’s continued dividend streak into 2025 underscores that operating resilience.
Numbers that matter. Abbott produced $45.13 billion in revenue and $11.74 billion in EBITDA, with a 56.5% gross margin, 13.47% operating margin, and 13.9% net margin. Revenue growth was healthy at 7.8% year over year, but earnings growth was negative 19.7%, which is a key reason it ranks below the strongest names here. The stock trades at 25.56 times trailing earnings and 16.64 times forward earnings, while next-year EPS is estimated at 6.0618 versus trailing EPS of 3.57, suggesting analysts expect a meaningful earnings rebound.
Recent momentum. Abbott’s recent earnings execution has been less consistent than some peers, with beats in only 3 of the last 7 quarters and several reports that merely matched expectations, including April 2026 at 1.15 versus 1.15 expected. Analyst sentiment is still constructive overall, with 4 Buy and 7 Hold ratings and no reported Sell count in our data, alongside an average target of $117.29. That leaves Abbott looking dependable, but not especially sharp on near-term earnings momentum.
What they do. Coca-Cola manufactures and sells nonalcoholic beverages globally, spanning sparkling soft drinks, water, sports drinks, coffee, tea, juice, dairy, and plant-based beverages. Its business is strengthened by a vast brand portfolio and a distribution model built around independent bottling partners, distributors, wholesalers, and retailers.
Why it fits. Coca-Cola is a classic Dividend King because beverage demand is recurring, brand equity is global, and the company has room to defend margins through pricing and mix. The February 2026 board action marking its 63rd consecutive annual dividend increase reinforces the point: this is a consumer-staples platform built to keep producing cash across many environments.
Numbers that matter. Coca-Cola generated $49.28 billion in revenue and $16.71 billion in EBITDA, with standout profitability metrics: 61.7% gross margin, 35.06% operating margin, and 27.8% net margin. Growth has also been solid for a mature staples company, with revenue up 12.1% year over year and earnings up 18.2%. The trade-off is valuation and leverage sensitivity in the quality model, as the stock sits at 25.03 times trailing earnings and 24.39 times forward earnings, contributing to a composite grade of B rather than something higher.
Recent momentum. Few companies in this group have matched Coca-Cola’s consistency lately: it has beaten earnings estimates in 7 of the last 7 quarters, including a 6.2% beat in April 2026 and a 3.6% beat in February 2026. Analysts are favorable, with 8 Buy, 3 Hold, and 1 Sell ratings, and the average target is $86.06. That mix of execution and sentiment keeps Coca-Cola firmly in the upper half of this ranking.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. Johnson & Johnson operates across two major healthcare engines: Innovative Medicine and MedTech. That means exposure to prescription drugs in areas such as oncology, immunology, neuroscience, and cardiovascular disease, alongside surgical, orthopedic, cardiovascular, and vision products used in hospitals and clinics worldwide.
Why it fits. J&J fits this list because healthcare demand is persistent and its portfolio is unusually diversified for a Dividend King. Innovative Medicine adds patent-backed earnings power, while MedTech brings procedural and device exposure, giving the company multiple cash-flow streams that can support dividend growth through different market cycles.
Numbers that matter. Johnson & Johnson delivered $96.36 billion in revenue and $34.33 billion in EBITDA, with a 68.0% gross margin, 27.41% operating margin, and 21.83% net margin. Revenue growth of 9.9% was healthy, but earnings growth was negative 52.9%, which clouds the near-term picture even though profitability remains strong. Valuation is not cheap at 27.46 times trailing earnings and 20.49 times forward earnings, but ROE of 26.42% and ROA of 8.42% still point to a high-quality operating base.
Recent momentum. J&J has beaten estimates in 5 of the last 7 quarters, though the most recent report was softer, with April 2026 EPS of 2.14 versus a 2.27 estimate, a 5.7% miss. Analyst sentiment reflects that balance: 4 Buy and 13 Hold ratings, with an average target of $252.87. This is still a high-caliber Dividend King, but the recent earnings path is less clean than the top three names on this list.
Market cap: $70.3B · Quality grade: B · Analyst consensus: Hold (avg target $95.84)
What they do. Colgate-Palmolive sells everyday consumer products through two segments: Oral, Personal and Home Care, and Pet Nutrition. Its portfolio spans toothpaste, toothbrushes, soaps, shampoos, cleaners, and Hill’s pet nutrition products, giving it a mix of staple household demand and a faster-growing pet category.
Why it fits. Colgate fits the Dividend Kings theme because many of its products are habitual purchases with strong brand recognition. Oral care, home care, and pet nutrition all tend to be resilient categories, and that repeat-purchase profile is exactly what supports long dividend streaks when economic conditions become less predictable.
Numbers that matter. Colgate generated $20.80 billion in revenue and $4.92 billion in EBITDA, with a 60.1% gross margin, 20.92% operating margin, and 10.04% net margin. Returns are strong, with ROE of 36.36% and ROA of 16.1%, and revenue growth of 8.4% remains healthy for a staples company. The main issue is valuation and a softer earnings trend: earnings growth was negative 5.9%, while the stock trades at 34.03 times trailing earnings and 22.99 times forward earnings.
Recent momentum. Colgate has beaten estimates in 6 of the last 7 quarters, but the latest report broke that streak, with May 2026 EPS of 0.80 versus a 0.95 estimate, a 15.8% miss. Analysts are split but still constructive overall, with 6 Buy, 7 Hold, and 1 Sell ratings, and an average target of $95.84. That recent stumble keeps it below the two highest-ranked names despite a very durable business model.
Pick #2Subscribers only
Subscribers see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This monthly screen focused on U.S.-listed Dividend Kings with market capitalizations above $500 million. From that universe, we ranked candidates by investment quality using a blend of profitability, revenue and earnings growth, earnings consistency, valuation context, analyst sentiment, and our composite quality grades derived from primary-source financial data. We then presented the final selections in countdown order, starting with No. 7 and ending with the top overall pick at No. 1. Because market data and analyst views change over time, the list is designed to refresh regularly rather than serve as a static ranking.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
